Baxter begins integrating Hillrom, faces supply chain pressures

Despite beating revenue expectations for 2021, Baxter International's stock was still down at market open on Thursday. The company reported revenues of $3.5 billion for the fourth quarter, up 10% from 2020, driven by better than expected growth in its renal care business. Like other medtechs, it saw a slowdown in surgical procedures due to healthcare staffing shortages during the pandemic.